Blood

Vol. 145, Issue 25 Issue 25 2025
20
Articles

Articles in this Issue

Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes

Patrick K. Reville, Bofei Wang, Jennifer Marvin-Peek et al. Jun 19, 2025 pp. 3015-3029 10.1182/blood.2024027244

Abstract Inflammation is increasingly recognized as a critical factor in acute myeloid leukemia (AML) pathogenesis. We performed blood-based proteomic profiling of 251 inflammatory p...

Socioeconomic factors and transplant access

Jun 19, 2025 pp. 3061-3061 10.1182/blood.2025029815

Disrupting HIT immune complexes as a new treatment for HIT

Beng H. Chong Jun 19, 2025 pp. 2939-2941 10.1182/blood.2025029232

Genetic challenges in the hole puncher

Randy Q. Cron Jun 19, 2025 pp. 2934-2936 10.1182/blood.2025029039

PI3Kγ in leukemia: class IB PI3 kinase reemerges as a cancer-intrinsic target

Qingyu Luo, Amanda L. Fortune, Andrew A. Lane Jun 19, 2025 pp. 2945-2953 10.1182/blood.2024027376

Abstract Phosphoinositide 3-kinase gamma (PI3Kγ), the only class IB PI3 kinase, is a cell-extrinsic immunotherapy target in solid tumors. PI3Kγ inhibition reprograms immunosuppressiv...

Prognostic biomarkers in MCL: insights from the SHINE trial on the impact of MCL35 score and <i>TP53</i> mutation status

Ciara L. Freeman, Srimathi Srinivasan, Brendan Hodkinson et al. Jun 19, 2025 pp. 3052-3056 10.1182/blood.2024026003

Abstract The MCL35 gene expression assay encompasses key risk features and stratified older patients with mantle cell lymphoma (MCL) using routine biopsies. In the SHINE trial, high-...

Maternal regulation of iron metabolism resolved?

Leon Kautz Jun 19, 2025 pp. 2942-2944 10.1182/blood.2025029469

Precision pre-HSCT conditioning by targeting cMPL

Markus G. Manz Jun 19, 2025 pp. 2933-2934 10.1182/blood.2025028772

The bone marrow NK-cell profile predicts MRD negativity in patients with multiple myeloma treated with daratumumab-based therapy

Charlotte L. B. M. Korst, Sabrin Tahri, Carolien Duetz et al. Jun 19, 2025 pp. 3007-3014 10.1182/blood.2024026455

Abstract Natural killer (NK) cells are important effector cells in antibody-based immune therapies for multiple myeloma (MM) through antibody-dependent cellular cytotoxicity. Here, w...

OSMR takes the leap: from NULISA to ELISA

Tobias Herold Jun 19, 2025 pp. 2938-2938 10.1182/blood.2025029317

Destabilization of PF4-antigenic complexes in heparin-induced thrombocytopenia

Lubica Rauova, Khalil Bdeir, Ann H. Rux et al. Jun 19, 2025 pp. 3030-3040 10.1182/blood.2024025653

Abstract Heparin-induced thrombocytopenia (HIT) is initiated by antibodies that recognize large antigenic complexes composed of multiple molecules of cationic platelet factor 4 (PF4)...

Severe oxidant hemolysis in a child with G6PD deficiency and Hb C trait

Connor Cocke, Weijie Li Jun 19, 2025 pp. 3060-3060 10.1182/blood.2025029037

cMPL-based purification and depletion of human hematopoietic stem cells: implications for pretransplant conditioning

Daisuke Araki, So Gun Hong, Nathaniel Linde et al. Jun 19, 2025 pp. 2978-2991 10.1182/blood.2024024636

Abstract The thrombopoietin:cMPL signaling axis is a critical regulator of early hematopoiesis. However, the utility of cMPL as a standalone marker for identifying long-term repopula...

Beyond genotype: challenges in predicting disease risk for carriers of biallelic perforin variants

Oliver Wegehaupt, Oleg Borisov, Elena Sieni et al. Jun 19, 2025 pp. 2992-3006 10.1182/blood.2024027954

Abstract Genetic screening for severe congenital immunohematological diseases offers potential for early intervention, particularly through preemptive allogeneic hematopoietic stem c...

How I treat type 1 plasminogen deficiency

Amy D. Shapiro, Charles Nakar Jun 19, 2025 pp. 2954-2965 10.1182/blood.2024026973

Abstract Type 1 plasminogen deficiency (PLGD), an ultrarare disorder caused by PLG pathogenic variants, results in decreased levels of immunoreactive and functional plasminogen. PLGD...

A natural head start to MRD negativity in multiple myeloma

Erin W. Meermeier Jun 19, 2025 pp. 2936-2937 10.1182/blood.2025028710

Access to AlloTx for AML: the value of the social phenotype

Gary Schiller Jun 19, 2025 pp. 2941-2942 10.1182/blood.2025028826

Safety and efficacy of a fitusiran antithrombin-based dose regimen in people with hemophilia A or B: the ATLAS-OLE study

Steven W. Pipe, Laurel A. Menapace, Chuanwu Zhang et al. Jun 19, 2025 pp. 2966-2977 10.1182/blood.2024027008

Abstract Fitusiran, a subcutaneous investigational small interfering RNA therapeutic, lowers antithrombin (AT) to increase thrombin generation and rebalance hemostasis in people wi...

Maternal <i>Tmprss6</i> is required for hepcidin suppression and fetal health

Katherine L. Fielding, Cavan Bennett, Anne Pettikiriarachchi et al. Jun 19, 2025 pp. 3056-3059 10.1182/blood.2024027563

Abstract The antenatal role of the hepcidin-regulating protease Tmprss6 has never been elucidated because knockout dams are infertile. Using an in vivo knockdown approach, we confirm...

Social determinants of health and access to allogeneic hematopoietic cell transplantation for acute myeloid leukemia

Natalie Wuliji, Salene M. W. Jones, Ted Gooley et al. Jun 19, 2025 pp. 3041-3051 10.1182/blood.2024027543

Abstract Whether allogeneic hematopoietic cell transplant (allo-HCT) to treat acute myeloid leukemia (AML) is equitably accessible regardless of social determinants of health (SDOH)...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page